Esperion Therapeutics Stock Current Valuation
| ESPR Stock | USD 2.15 0.03 1.42% |
Valuation analysis of Esperion Therapeutics helps investors to measure Esperion Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 11/19/2024, Enterprise Value Over EBITDA is likely to drop to -5.37. In addition to that, Enterprise Value Multiple is likely to drop to -5.37. Fundamental drivers impacting Esperion Therapeutics' valuation include:
Price Book 98.4236 | Enterprise Value 547.9 M | Enterprise Value Ebitda (3.86) | Price Sales 1.4338 | Forward PE 1.5588 |
Undervalued
Today
Please note that Esperion Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Esperion Therapeutics is based on 3 months time horizon. Increasing Esperion Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Esperion stock is determined by what a typical buyer is willing to pay for full or partial control of Esperion Therapeutics. Since Esperion Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Esperion Stock. However, Esperion Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.15 | Real 4.3 | Target 11.13 | Hype 2.13 |
The intrinsic value of Esperion Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Esperion Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Esperion Therapeutics helps investors to forecast how Esperion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Esperion Therapeutics more accurately as focusing exclusively on Esperion Therapeutics' fundamentals will not take into account other important factors: Esperion Therapeutics Company Current Valuation Analysis
Esperion Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Esperion Therapeutics Current Valuation | 547.87 M |
Most of Esperion Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Esperion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Esperion Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Esperion Therapeutics is extremely important. It helps to project a fair market value of Esperion Stock properly, considering its historical fundamentals such as Current Valuation. Since Esperion Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Esperion Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Esperion Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Esperion Current Valuation Historical Pattern
Today, most investors in Esperion Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Esperion Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Esperion Therapeutics current valuation as a starting point in their analysis.
Esperion Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Esperion Therapeutics has a Current Valuation of 547.87 M. This is 96.19% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 96.7% higher than that of the company.
Esperion Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Esperion Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Esperion Therapeutics could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics of similar companies.Esperion Therapeutics is currently under evaluation in current valuation category among its peers.
Esperion Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Esperion Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Esperion Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Esperion Fundamentals
| Return On Equity | -2.61 | ||||
| Return On Asset | 0.0384 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 547.87 M | ||||
| Shares Outstanding | 197.04 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 66.32 % | ||||
| Number Of Shares Shorted | 33.46 M | ||||
| Price To Earning | (8.19) X | ||||
| Price To Book | 98.42 X | ||||
| Price To Sales | 1.43 X | ||||
| Revenue | 116.33 M | ||||
| Gross Profit | (70.42 M) | ||||
| EBITDA | (150.11 M) | ||||
| Net Income | (209.25 M) | ||||
| Cash And Equivalents | 185.84 M | ||||
| Cash Per Share | 2.79 X | ||||
| Total Debt | 540.95 M | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | (1.89) X | ||||
| Cash Flow From Operations | (135.49 M) | ||||
| Short Ratio | 10.38 X | ||||
| Earnings Per Share | (0.67) X | ||||
| Price To Earnings To Growth | (4.78) X | ||||
| Target Price | 7.51 | ||||
| Number Of Employees | 240 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 417.71 M | ||||
| Total Asset | 205.8 M | ||||
| Retained Earnings | (1.55 B) | ||||
| Working Capital | 44.84 M | ||||
| Current Asset | 214.39 M | ||||
| Current Liabilities | 5.62 M | ||||
| Net Asset | 205.8 M |
About Esperion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Esperion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Esperion Stock
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.8 | GSK | GlaxoSmithKline PLC ADR | PairCorr |
| 0.76 | OGN | Organon | PairCorr |
| 0.7 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.7 | NVS | Novartis AG ADR Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.